Filtered By:
Source: LANCET
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 186 results found since Jan 2013.
Department of Error Department of Error
The AVERT Trial Collaboration group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet 2015; 386: 46–55—The column headings of figure 2 in the appendix of this Article have been changed from “OR [odds ratio]” to “ES [effect size]”. This correction has been made to the online version as of May 7, 2015, and the printed version is correct.
Source: LANCET - May 7, 2015 Category: Journals (General) Tags: Department of Error Source Type: research
Articles Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial
First mobilisation took place within 24 h for most patients in this trial. The higher dose, very early mobilisation protocol was associated with a reduction in the odds of a favourable outcome at 3 months. Early mobilisation after stroke is recommended in many clinical practice guidelines worldwide, and our findings should affect clinical practice by refining present guidelines; however, clinical recommendations should be informed by future analyses of dose–response associations.
Source: LANCET - April 16, 2015 Category: Journals (General) Authors: The AVERT Trial Collaboration group Tags: Articles Source Type: research
Correspondence Thrombolysis in acute stroke
I read with interest the meta-analysis by Jonathan Emberson and colleagues,1 but would have appreciated heterogeneity assessments for the major outcomes in the meta-analysis.
Source: LANCET - April 10, 2015 Category: Journals (General) Authors: David H Newman Tags: Correspondence Source Type: research
Correspondence Thrombolysis in acute stroke – Authors' reply
We thank the correspondents for their interest in our meta-analysis of individual patient data from trials of alteplase for patients with acute ischaemic stroke.1
Source: LANCET - April 10, 2015 Category: Journals (General) Authors: Jonathan Emberson, Kennedy R Lees, Patrick Lyden, Colin Baigent, Peter Sandercock, Werner Hacke, on behalf of the Stroke Treatment Trialists' Collaboration Tags: Correspondence Source Type: research
Correspondence Thrombolysis in acute stroke
In their meta-analysis of intravenous thrombolysis with alteplase for acute ischaemic stroke, Jonathan Emberson and colleagues (Nov 29, p 1929)1 concluded that the increased risk of early death from intracranial haemorrhage in patients taking alteplase was offset by an increase in disability-free survival. This interpretation gives the impression that the high level of mortality in the acute phase tends to diminish with time, but that is not the case. In the latest Cochrane analysis of thrombolysis for acute ischaemic stroke,2 thrombolysis gave no survival advantage between 7 days after thrombolysis and the end of follow-up.
Source: LANCET - April 10, 2015 Category: Journals (General) Authors: Peter Appelros, Andreas Terént Tags: Correspondence Source Type: research
Editorial Thrombolysis for stroke: clinical judgment at its apogee
In the Correspondence section of today's Lancet, we publish a selection of letters challenging the report by Jonathan Emberson and colleagues on the effect of treatment delay, age, and stroke severity on the effects of thrombolysis with alteplase for acute ischaemic stroke. Emberson and colleagues concluded from their meta-analysis of 6756 patients that despite early increases in fatal intracranial haemorrhage, alteplase improves the overall likelihood of a good stroke outcome at 3–6 months when delivered within 4·5 h of the initial stroke symptoms, with earlier treatment increasing proportional benefit, irrespective of...
Source: LANCET - April 10, 2015 Category: Journals (General) Authors: The Lancet Tags: Editorial Source Type: research
Case Report Reversible right heart failure after medullary stroke
In May, 2013, a 73-year-old woman presented to our clinic with drowsiness. She had had a left medullary stroke due to atrial fibrillation 7 months earlier (figure) and was taking oral anticoagulants. Since her stroke she had had fragmented sleep and excessive daytime sleepiness, and during the previous 4 months had developed facial and generalised oedema, which had become much worse in the week before admission, and was associated with anuria and drowsiness. On examination she was afebrile, blood pressure was 141/121 mm Hg, pulse was 80 beats per min and irregular, and jugular venous pressure was raised.
Source: LANCET - April 3, 2015 Category: Journals (General) Authors: Han-Gil Jeong, Dae Lim Koo, Hyunwoo Nam, Hyung-Min Kwon Tags: Case Report Source Type: research
Comment Gestational hypertension before term: observe or deliver?
Pre-eclampsia and other hypertensive disorders of pregnancy are common, and carry risks for both mother and baby. The only cure is delivery. Severe hypertension and severe pre-eclampsia are associated with increased risk of maternal morbidities such as stroke, coagulopathy, and eclampsia, and of maternal death.1 For these women, if gestation is over 34 weeks, the aim should be medical management with timely delivery. If gestation is less than 34 weeks, expectant care with stabilisation and careful monitoring of the woman to delay delivery might be better for the baby than immediate delivery.
Source: LANCET - March 25, 2015 Category: Journals (General) Authors: Jim Thornton, Lelia Duley Tags: Comment Source Type: research
Series Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, including causing serious bleeding such as intracranial haemorrhage and the need for anticoagulation monitoring. In part related to these limitations, they are used in only about half of patients who should be treated according to guideline recommendations. In the past decade, oral agents have been developed that directly block the activity of thrombin (factor IIa), as well as drugs that directly inhibit activated factor X (Xa), which is ...
Source: LANCET - March 14, 2015 Category: Journals (General) Authors: Freek W A Verheugt, Christopher B Granger Tags: Series Source Type: research
Articles Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Digoxin treatment was associated with a significant increase in all-cause mortality, vascular death, and sudden death in patients with AF. This association was independent of other measured prognostic factors, and although residual confounding could account for these results, these data show the possibility of digoxin having these effects. A randomised trial of digoxin in treatment of AF patients with and without heart failure is needed.
Source: LANCET - March 6, 2015 Category: Journals (General) Authors: Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, Jonathan L Halperin, Günter Breithardt, Daniel E Singer, Kenneth W Mahaffey, Graeme J Hankey, Scott D Berkowitz, Christopher C Nessel, Keith A A Fox, Robert M Califf, Jonathan P Piccini, Manesh R Pa Tags: Articles Source Type: research
Department of Error Department of Error
The ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 2015; 385: 617–28—In figure 1 in this Article, the number of patients assigned to the GTN patch who completed assessment on day 7 should have been 1996 rather than 1966. Data for TICS-M score and verbal fluency score for both analyses in table 2 were incorrect; the table has been corrected.
Source: LANCET - February 14, 2015 Category: Journals (General) Tags: Department of Error Source Type: research
Comment Preventive antibiotic therapy in stroke: PASSed away?
Stroke not only impairs neurological function but also leads to severe medical complications,1 of which infections, especially pneumonia, are the most important.2 In the past 10 years, epidemiological data have consistently shown that post-stroke infections are associated with increased mortality and poor neurological outcomes.3–5 Dysphagia and a stroke-induced immunodepressive state are risk factors for post-stroke infections.6 Despite general measures for infection prevention, pneumonia remains a common and severe clinical challenge, even for patients treated in specialised stroke units5,7 that are known to reduce the ...
Source: LANCET - January 20, 2015 Category: Journals (General) Authors: Andreas Meisel Tags: Comment Source Type: research
Articles The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial
Preventive ceftriaxone does not improve functional outcome at 3 months in adults with acute stroke. The results of our trial do not support the use of preventive antibiotics in adults with acute stroke.
Source: LANCET - January 20, 2015 Category: Journals (General) Authors: Willeke F Westendorp, Jan-Dirk Vermeij, Elles Zock, Imke J Hooijenga, Nyika D Kruyt, Hans J L W Bosboom, Vincent I H Kwa, Martijn Weisfelt, Michel J M Remmers, Robert ten Houten, A H C M (Tobien) Schreuder, Sarah E Vermeer, Ewout J van Dijk, Diederik W J Tags: Articles Source Type: research
